Inclusion Criteria:

   - Any patient between the age of 18 and 70 years of age and able to give informed
   consent

   - GFR by Cockcroft-Gault or MDRD equations <90 mls/min and >30 mls/min

   - Greater than or equal to 1000 mg of proteinuria/24 hours while on stable ACEi, ARB or
   renin inhibitor therapy for 2 months. Patients receiving combination ACE or ARB or
   ACEi and a renin inhibitor for 2 months will only require 500mg/24 hours

   - Blood pressure <130/80 mmHg. The presence of hypertension is not required for study
   entry, but any patient requiring long term hypertensive medications must have blood
   pressure controlled <130-80 mmHg, to be considered eligible for the study

   - Female patients with IgA will be considered eligible for study entry if they have a
   negative urine or serum pregnancy test at the time of screening are agreeable to 2
   years of contraception

   - Biopsy proven IgA nephropathy and clinical features consistent with Henoch Schonlein
   Purpura will be considered eligible for the study

   - Able to swallow the oral medications

Exclusion Criteria

   - Clinical and histologic evidence of IgA predominant Lupus nephritis

   - Clinical and histologic evidence of idiopathic IgA forms of membranoproliferative
   glomerulonephritis

   - Clinical evidence of cirrhosis, chronic active liver disease or known infection with
   hepatitis B, C or HIV

   - Estimated GFR <30 ml/min/1.73m² at the time of screening

   - Greater than 50% glomerular senescence or cortical scarring on renal biopsy

   - Active systemic infection or history of serious infection within one month of entry

   - History of Crohn's disease or Celiac Sprue

   - Positive pregnancy test or breast feeding at time of study entry or unwilling to
   comply with contraceptive measures

   - Current or recent (within 30 days) exposure to any investigational drug

   - Serum Cr >3.5 mg/dl or Modification of Diet in Renal Disease (MDRD) calculated GFR <30
   mls/min

   - Patients receiving >6 months therapy with oral prednisone or glucocorticoid equivalent

   - Live vaccine within 28 days of study enrollment.

General Safety & Laboratory Exclusion Criteria

   - Patients with anaphylaxis and/or known allergic reactions to Rituximab

   - Hemoglobin: <8.5 gm/dL

   - Platelets: <100,000/mm

   - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 x Upper Limit
   of Normal unless related to primary disease.

   - Previous Treatment with Rituximab(MabThera®/Rituxan®)

   - Previous treatment with Natalizumab(Tysabri®)

   - History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
   antibodies

   - History of recurrent significant infection or recurrent bacterial infections

   - Known active bacterial, viral fungal mycobacterial or atypical mycobacterial
   infections, but excluding fungal infections of nail beds

   - Any major episode of infection requiring hospitalization or treatment with i.v.
   antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to
   screening

   - Ongoing use of high dose steroids(>10 mg/day)or unstable steroid dose in the past 4
   weeks

   - Lack of peripheral venous access

   - History of drug, alcohol, or chemical abuse within 6 months prior to screening

   - Pregnancy (a negative serum or urine pregnancy test will be performed for all women of
   childbearing potential no later than 7 days prior to treatment) or lactation

   - Concomitant or previous malignancies, with the exception of adequately treated basal
   or squamous cell carcinoma of the skin or carcinoma in situ of the cervix

   - History of psychiatric disorder that would interfere with normal participation in this
   protocol

   - Significant cardiac or pulmonary disease (including obstructive pulmonary disease)

   - Any other disease, metabolic dysfunction, physical examination finding, or clinical
   laboratory finding giving reasonable suspicion of a disease or condition that
   contraindicates the use of an investigational drug or that may affect the
   interpretation of the results or render the patient at high risk from treatment
   complication

   - Inability to comply with study and follow-up procedures